These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 17620430

  • 1. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
    Rosanò L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A.
    Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
    [Abstract] [Full Text] [Related]

  • 2. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
    Rosanò L, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG, Bagnato A.
    Cancer Res; 2007 Jul 01; 67(13):6351-9. PubMed ID: 17616694
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
    Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Natali PG, Bagnato A.
    Can J Physiol Pharmacol; 2010 Jun 01; 88(6):676-81. PubMed ID: 20628434
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A.
    Cancer Res; 2003 May 15; 63(10):2447-53. PubMed ID: 12750265
    [Abstract] [Full Text] [Related]

  • 5. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.
    Growcott JW.
    Anticancer Drugs; 2009 Feb 15; 20(2):83-8. PubMed ID: 19065106
    [Abstract] [Full Text] [Related]

  • 6. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.
    Rosanò L, Di Castro V, Spinella F, Decandia S, Natali PG, Bagnato A.
    Exp Biol Med (Maywood); 2006 Jun 15; 231(6):1132-5. PubMed ID: 16741063
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.
    Rosanò L, Spinella F, Di Castro V, Natali PG, Bagnato A.
    J Cardiovasc Pharmacol; 2004 Nov 15; 44 Suppl 1():S132-5. PubMed ID: 15838262
    [Abstract] [Full Text] [Related]

  • 8. Endothelin-A receptor in gastric cancer and enhanced antitumor activity of trastuzumab in combination with the endothelin-A receptor antagonist ZD4054.
    Shen W, Xi H, Li C, Bian S, Cheng H, Cui J, Wang N, Wei B, Huang X, Chen L.
    Ann N Y Acad Sci; 2019 Jul 15; 1448(1):30-41. PubMed ID: 30937921
    [Abstract] [Full Text] [Related]

  • 9. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A.
    Clin Cancer Res; 2011 Apr 15; 17(8):2350-60. PubMed ID: 21220476
    [Abstract] [Full Text] [Related]

  • 10. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
    Smollich M, Götte M, Fischgräbe J, Macedo LF, Brodie A, Chen S, Radke I, Kiesel L, Wülfing P.
    Breast Cancer Res Treat; 2010 Sep 15; 123(2):345-57. PubMed ID: 19943105
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A.
    Clin Cancer Res; 2004 Jul 15; 10(14):4670-9. PubMed ID: 15269139
    [Abstract] [Full Text] [Related]

  • 12. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.
    Spinella F, Rosanò L, Di Castro V, Decandia S, Albini A, Nicotra MR, Natali PG, Bagnato A.
    Mol Cancer Ther; 2006 Jun 15; 5(6):1483-92. PubMed ID: 16818507
    [Abstract] [Full Text] [Related]

  • 13. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.
    Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra MR, Natali PG, Venuti A.
    Cancer Res; 2002 Nov 15; 62(22):6381-4. PubMed ID: 12438219
    [Abstract] [Full Text] [Related]

  • 14. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.
    Warren R, Liu G.
    Expert Opin Investig Drugs; 2008 Aug 15; 17(8):1237-45. PubMed ID: 18616419
    [Abstract] [Full Text] [Related]

  • 15. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK.
    Clin Cancer Res; 2005 Jul 01; 11(13):4923-33. PubMed ID: 16000591
    [Abstract] [Full Text] [Related]

  • 16. Endothelin-1 acts as a survival factor in ovarian carcinoma cells.
    Del Bufalo D, Di Castro V, Biroccio A, Salani D, Rosanò L, Spinella F, Bagnato A.
    Clin Sci (Lond); 2002 Aug 01; 103 Suppl 48():302S-305S. PubMed ID: 12193109
    [Abstract] [Full Text] [Related]

  • 17. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer.
    Jiang H, Feng Y.
    Int J Gynecol Cancer; 2006 Aug 01; 16 Suppl 1():405-12. PubMed ID: 16515634
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma.
    Mai HQ, Zeng ZY, Feng KT, Ye YL, Zhang CQ, Liang WJ, Guo X, Mo HY, Hong MH.
    Cancer Sci; 2006 Dec 01; 97(12):1388-95. PubMed ID: 17032313
    [Abstract] [Full Text] [Related]

  • 19. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK.
    Mol Cancer Ther; 2015 Dec 01; 14(12):2677-86. PubMed ID: 26516159
    [Abstract] [Full Text] [Related]

  • 20. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation.
    Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosanò L, Trisciuoglio D, Spinella F, Bagnato A.
    Mol Pharmacol; 2002 Mar 01; 61(3):524-32. PubMed ID: 11854432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.